ArticleFrontiers in immunology2026
Interleukin-10 at the crossroads of immunity in TLR7-induced lupus.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease characterized by dysregulated innate and adaptive immunity. Soluble mediators like cytokines critically shape immune responses and sustain chronic inflammation. Interleukin-10 (IL-10), typically anti-inflammatory, also exerts pro-inflammatory effects in SLE, for example by promoting B cell differentiation and autoantibody production. Despite growing interest in IL-10 as a biomarker or therapeutic target, its dual roles have been reported inconsistently, likely reflecting differences in disease context, clinical presentation, disease activity, and the local microenvironment, an issue addressed in this work. Methods: To further clarify its role in lupus, we investigated its function in a toll-like receptor 7 (TLR7) agonist-induced murine model. By administering an antagonistic anti-IL-10 receptor (anti-IL-10R) antibody, we investigated its broad Results: IL-10 showed both pro- and anti-inflammatory effects on immune cells; however, overall, it modestly limited disease progression, indicating that, under the given conditions, its regulatory, anti-inflammatory effects may slightly outweigh its pro-inflammatory actions. The most pronounced effects were seen in the CD4 T-cell compartment, where IL-10R blockade increased IL-17, while reducing regulatory T cell (T Conclusion: Collectively, these findings highlight dual role of IL-10 in lupus and suggest how a single cytokine may trigger opposing immune effects via shared signaling pathways. Further research is needed to clarify how a pro-inflammatory context directs IL-10 signaling toward stimulatory or suppressive outcomes, informing new therapeutic strategies for diseases such as SLE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.